中国药物警戒 ›› 2017, Vol. 14 ›› Issue (5): 270-273.

• 基础与临床研究专栏 • 上一篇    下一篇

棕榈酸帕利哌酮治疗中青年精神分裂症200例的临床疗效与安全性观察

朱倩芸1, 陈仁云2*, *   

  1. 1 武汉市优抚医院一病区 武汉 430023;
    2 武汉市社会福利院 武汉 430023
  • 收稿日期:2017-07-12 修回日期:2017-07-12 出版日期:2017-05-20 发布日期:2017-07-12
  • 通讯作者: 陈仁云,硕士,副主任医师,老年性精神障碍诊断及治疗。E-mail：89768727@qq.com。

Clinical Efficacy and Safety of Paliperidone Palmitate in The Treatment of 200 Cases Young and Middle-aged Patients with Schizophrenia

ZHU Yun-qian1, CHEN Yun-ren2, *   

  1. 1 The first lesion, special care hospital of Wuhan city , Wuhan 430023 China;
    2 The social welfare institute of Wuhan city, Wuhan 430023, China
  • Received:2017-07-12 Revised:2017-07-12 Online:2017-05-20 Published:2017-07-12

PDF (PC)

69

摘要： 目的 观察棕榈酸帕利哌酮对中青年精神分裂症的疗效、社会功能的改善以及安全性的影响。方法 患者按照就诊顺序交叉分为研究组（棕榈酸帕利哌酮）和对照组（利培酮）。治疗周期为24周,治疗前、治疗1、4、8、16、24周后对患者精神病症状、生活质量和社会功能、药物安全性分别进行检测,检测结果根据阳性与阴性症状量表（PANSS）、临床总体印象-严重度量表（CGI-S）,人际和社会能力量表（PSP）,药物副作用量表（TESS）评定。结果 入组200例患者,共有191例患者完成研究,研究组96例,对照组95例。治疗前两组的PANSS、CGI-S和PSP均无显著性差异。分组治疗24周后PANSS和TESS评分均有所改善,但组间比较差异均无统计学差异。分组治疗各时期CGI-S和PSP评分较治疗前均有所改善,其中棕榈酸帕利哌酮改善更为明显,且两组组间差异有统计学意义（P<0.05）。结论 棕榈酸帕利哌酮能有效改善中青年精神分裂症患者的症状,提高患者的社会功能且具有较低的药物不良反应。

关键词: 棕榈酸帕利哌酮, 利培酮, 精神分裂症, 安全性, 社会功能

Abstract: Objective To observe the clinical efficacy and safety of paliperidone palmitate in treatment of 200 cases of young and middle-aged patients with schizophrenia. Methods All patients were divided into research group (paliperidone palmitate) and control group (risperidone) in accordance with registration order. The whole treatment cycle lasted for 24 weeks. Psychotic symptoms, quality of life, social function and drug safety were tested respectively at these time points, including before treatment, treatment of 1, 4, 8, 16, 24 weeks. The positive and negative symptoms scale (PANSS), clinical global impression-severity (CGI-S), personal and social performance scale (PSP) and treatment emergent symptom scale (TESS) were regarded as the evaluation indicators. Results 200 patients participated in the study, 191 cases finished the research, 96 cases in paliperidone palmitate group, 95 cases in risperidone group. Before treatment, PANSS, CGI-S and PSP showed no significant difference between two groups. After 24-week treatment, PANSS and TESS were improved, but the comparative differences between two groups were not meaningful. CGI-S and PSP were improved at each time point of treatment, and improvement was more obvious in paliperidone palmitate group. Meanwhile, differences between two groups were statically significant (P<0.05). Conclusion Paliperidone palmitate, which has few adverse drug reactions, can effectively improve the symptoms of the youth patients with schizophrenia, and enhance their social function.

Key words: paliperidone, palmitate,risperidone,schizophrenia,drug, safety,social, function

中图分类号: